{"analyses":[{"ciLowerLimit":"-0.652","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.532","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.302","estimateComment":"The treatment can be considered beneficial if the mean difference (treatment - control) slope is positive","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.84","paramType":"Slope","paramValue":"-0.060","statisticalComment":"The treatment effect was determined by testing the significance of the group by time interaction in GEE using a one degree-of-freedom (df) test.","statisticalMethod":"Generalized Estimating Equation (GEE)"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.4549","value":"28.5362"},{"groupId":"OG001","spread":"0.4764","value":"28.4339"}]}],"title":"BL"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.4738","value":"28.5409"},{"groupId":"OG001","spread":"0.5799","value":"27.6866"}]}],"title":"6m"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.483","value":"29.6121"},{"groupId":"OG001","spread":"0.4918","value":"28.1085"}]}],"title":"12m"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.4951","value":"27.8219"},{"groupId":"OG001","spread":"0.596","value":"27.8891"}]}],"title":"18m"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.5073","value":"28.0302"},{"groupId":"OG001","spread":"0.5901","value":"28.5953"}]}],"title":"24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"76"}],"units":"Participants"}],"description":"A measure to assess preload and afterload (in %). The mean is reported by arm at each timepoint with corresponding standard errors.","dispersionType":"Standard Error","groups":[{"description":"Patients received Carvedilol PO delivered at 6.25 mg twice daily (for a total dose of 12.5 mg per day) for 24 months.","id":"OG000","title":"Arm I (Carvedilol)"},{"description":"Patients received Placebo PO delivered at 6.25 mg twice daily (for a total dose of 12.5 mg per day) for 24 months.","id":"OG001","title":"Arm II (Placebo)"}],"paramType":"MEAN","populationDescription":"We excluded 31 participants who did not have a second time point assessment of echocardiography, resulting in 151 analyzable participants.","reportingStatus":"POSTED","timeFrame":"Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation","title":"Average Fractional Shortening","type":"SECONDARY","unitOfMeasure":"percent"}